Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute and Amgen Reach Strategic Cooperation

The Guangdong–Hong Kong–Macao Greater Bay Area International Clinical Trial Institute (GBAICTI) and global biotechnology company Amgen announced today that they have signed a memorandum of understanding to work together to strengthen Hong Kong and the Guangdong–Hong Kong–Macao Greater Bay Area’s medical capabilities and improve patient treatment outcomes. Hong Kong has strong clinical, academic, and medical strengths, providing a foundation for the Greater Bay Area’s…
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned